Pfizer 3Q 2026: Revenue $16.58B, Net income $3.24B, EPS $0.56— 10-Q Summary
Pfizer reported 3Q 2026 revenue of $16.58B, down 0.4% YoY, with net income of $3.24B, down 8.4%, and EPS of $0.56, down 9.7%. Nine-month revenue rose 2% to $46.1B, or 7% excluding COVID-19 products. Eliquis and other drugs grew, while Prevnar and COVID-19 products declined. Pfizer expects no material impact from Medicare price changes and targets $2.5B in additional savings through 2029.
How this was made
The 30-second read
Why it matters
The earnings miss may trigger short‑term sell pressure, but long‑term outlook could benefit from cost‑saving initiatives.
Market read
First‑report earnings data for a large‑cap pharma; likely influences PFE price and sector sentiment.
What to watch
Cost‑program savings of $2.5B through 2029 may improve margins in later quarters.
Background
Pfizer's Q3 2026 earnings were released via a 10‑Q filing, showing slight declines across revenue, net income, and EPS.
Ticker impact
Pfizer reported Q3 2026 revenue of $16.58B, net income $3.24B, and diluted EPS $0.56, all down YoY.
likely pressure as the market prices in the revenue and earnings decline
Large‑cap pharma with modest YoY declines; investors typically react negatively to earnings below expectations.
Market effects
May weigh on broader pharma sector as peers could face similar margin pressure.
US market likely sees modest pullback in health‑care indices.
Limited to investors with exposure to US‑listed pharma stocks.
Counterpoint
If the decline is seen as temporary and pipeline remains strong, the dip could be a buying opportunity.
Key entities
- companyPfizer Inc.
US‑listed pharmaceutical giant reporting Q3 2026 results.
